October 19, 2018 / 2:30 PM / 25 days ago

BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results

Oct 19 (Reuters) - Incyte Corp:

* PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC

* ADVERSE EVENTS (AES) WERE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND NO NEW SAFETY SIGNALS WERE OBSERVED IN STUDY

* CLINICAL FINDINGS FROM ONGOING STUDY INDICATE SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY REPORTED DATA RESULTS

* NOVARTIS HAS EXCLUSIVE DEVELOPMENT & COMMERCIALIZATION WORLDWIDE RIGHTS TO CAPMATINIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below